ReviewJournal of clinical hypertension (Greenwich, Conn.)2011
Central sympatholytic drugs.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Drugs in R&D · 2017Pooled it
- 7th Brazilian Guideline of Arterial Hypertension: Chapter 7 - Pharmacological TreatmentArquivos brasileiros de cardiologia · 2016Guideline
- Article
- Current Management of Resistant Hypertension in Patients with Intracerebral Hemorrhage.International journal of molecular sciences · 2026Review
- The Heart-Brain Axis in the Context of Cardiovascular Disease.Physiology (Bethesda, Md.) · 2026Review
- Guanfacine as a potential preventive therapy for chronic migraine: a mechanistic hypothesis.Frontiers in neurology · 2026Article
- Guanfacine as an Adjunct Treatment for Complex Post-Traumatic Stress Disorder: A Case Report.Journal of the Korean Academy of Child and Adolescent Psychiatry · 2025Article
- Case 16-2023: A 13-Year-Old Boy with Depression and Hypotension.The New England journal of medicine · 2023Article
- Comparison of the cardiovascular effects of immobilization with three different drug combinations in free-ranging African lions.Conservation physiology · 2023Article
- Blood pressure reduction induced by chronic intracerebroventricular or peroral clonidine administration in rats with salt-dependent or angiotensin II-dependent hypertension.Physiological research · 2022Article
- Brazilian Guidelines of Hypertension - 2020.Arquivos brasileiros de cardiologia · 2021Article
- Melatonin attenuates renal sympathetic overactivity and reactive oxygen species in the brain in neurogenic hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Article
- Sustainability of blood pressure reduction in black barbershops.Current opinion in cardiology · 2019Review
- Carotid baroreflex activation therapy for resistant hypertension.Nature reviews. Cardiology · 2015Review
- Regional differences in sexually dimorphic protein expression in the spontaneously hypertensive rat (SHR).Molecular and cellular biochemistry · 2012Article
- A compendium of antihypertensive therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key points• Central sympatholytic drugs reduce blood pressure mainly by stimulating central α(2) -adrenergic receptors in the brainstem centers, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and peripheral circulation. • This class of drugs, however, is currently used mainly as fourth-line (or beyond) drug therapy for hypertension because of side effects of drowsiness, fatigue, and dry mouth. • Rebound hypertension is also another major concern in certain drugs with a short half-life, particularly in patients who are nonadherent to the regimen. Therefore, their use on a "PRN" basis for treatment of blood pressure surge in the absence of symptoms or acute target complications should also be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.